DUBLIN, Dec. 4, 2020 /PRNewswire/ — The “Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.
The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.
Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.
The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period
Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.
Oncology segment accounted for highest CAGR
Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Dynamics
184.108.40.206 Rising Prevalence of Chronic Diseases, Genetic Disorders, and Cancer
220.127.116.11 Rising Investments in Regenerative Medicine Research
18.104.22.168 Growing Pipeline of Regenerative Medicine Products
22.214.171.124 Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
126.96.36.199 High Cost of Cell and Gene Therapies
188.8.131.52 Implementation of the 21st Century Cures Act
184.108.40.206 Rising Demand for Organ Transplantations
5.3 Impact of the COVID-19 Pandemic on the Regenerative Medicine Market
6 Regenerative Medicine Market, by Product
6.2 Tissue-Engineered Products
6.2.1 Rising Prevalence of Chronic Wounds to Drive the Market Growth
6.3 Cell Therapies
6.3.1 Autologous Therapies
220.127.116.11 Autologous Therapies Segment to Register the Highest Growth in the Cell Therapies Market
6.3.2 Allogeneic Therapies
18.104.22.168 Rising Incidence of Chronic Conditions to Drive the Market Growth
6.4 Gene Therapies
6.4.1 Growing Number of Cancer Cases to Drive Market Growth
6.5 Progenitor & Stem Cell Therapies
6.5.1 Growing Product Pipeline to Support the Growth of this Segment
7 Regenerative Medicine Market, by Application
7.2 Musculoskeletal Disorders
7.2.1 Increasing Prevalence of Orthopedic Disorders to Drive the Growth of this Application Segment
7.3.1 Increasing Incidence of Cancer to Support Market Growth
7.4 Wound Care
7.4.1 Rising Prevalence of Chronic Conditions to Drive the Growth of this Segment
7.5.1 Rising Incidence of Oral Disorders to Drive the Market Growth
7.6 Ocular Disorders
7.6.1 Rising Product Approvals to Drive Market Growth
8 Regenerative Medicine Market, by Region
9 Competitive Landscape
9.2 Cell Therapy Market Share Analysis
9.3 Gene Therapy Market Share Analysis
9.4 Tissue Engineering Market Ranking
9.5 Competitive Scenario
9.5.1 Product Launches & Regulatory Approvals
10 Company Evaluation Matrix and Company Profiles
10.1 Company Evaluation Matrix Definition and Methodology
10.1.1 Vendor Inclusion Criteria
10.1.3 Emerging Leaders
10.2 Company Evaluation Matrix for Start-Ups (2019)
10.2.1 Progressive Companies
10.2.2 Responsive Companies
10.2.3 Starting Blocks
10.2.4 Dynamic Companies
10.3 Company Profiles
- 3M Group
- Amgen, Inc.
- Anterogen Co., Ltd.
- APAC Biotech
- Aspect Biosystems
- Bluebird Bio
- Corestem, Inc.
- Integra Lifesciences Holdings Corporation
- Kite Pharma
- Medipost Co., Ltd.
- Medtronic plc
- Mimedx Group
- Novartis Ag
- Organogenesis Inc.
- Orthocell Ltd.
- Shenzhen Sibiono Genetech Co., Ltd.
- Smith & Nephew plc
- Spark Therapeutics
- Stryker Corporation
- Takeda Pharmaceutical Company Limited
- Tego Science, Inc.
- Vericel Corporation
- Zimmer Biomet
For more information about this report visit https://www.researchandmarkets.com/r/ntt3w3
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets